<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="168352">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02147899</url>
  </required_header>
  <id_info>
    <org_study_id>SYM-1219-201</org_study_id>
    <nct_id>NCT02147899</nct_id>
  </id_info>
  <brief_title>A Phase 2 Study of SYM-1219 to Treat Bacterial Vaginosis</brief_title>
  <official_title>A Phase 2, Multi-center, Prospective, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effectiveness and Safety of SYM-1219 for the Treatment of Women With Bacterial Vaginosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Symbiomix Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Symbiomix Therapeutics</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to test the safety and effectiveness of the oral
      investigational new drug, SYM-1219, for the treatment of bacterial vaginosis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">November 2014</completion_date>
  <primary_completion_date type="Anticipated">November 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of Patients with Clinical Cure</measure>
    <time_frame>Study Days 21-30</time_frame>
    <safety_issue>No</safety_issue>
    <description>Clinical Cure is a composite endpoint determined by normalization of the vaginal discharge and a negative KOH &quot;Whiff&quot; test and Clue cells less than 20% of the total epithelial cells on microscopic examination of the vaginal wet mount.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients with Adverse Events</measure>
    <time_frame>Study Days 8-10 and Study Days 21-30</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients with Therapeutic Cure</measure>
    <time_frame>Study Days 21-30</time_frame>
    <safety_issue>No</safety_issue>
    <description>Clinical Cure and Normalization of the Nugent score.  The Nugent score is based on a microscopic assessment of a Gram stain of the vaginal fluid.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients with a Normal Nugent score</measure>
    <time_frame>Study Days 21-30</time_frame>
    <safety_issue>No</safety_issue>
    <description>The Nugent score is determined by a microscopic assessment of a Gram stain of vaginal fluid.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Patient-Reported Symptom Assessment</measure>
    <time_frame>Daily on Study Days 1-7</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Number of Patients with Normal Vaginal Fluid pH</measure>
    <time_frame>Study Days 21-30</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Bacterial Vaginosis</condition>
  <arm_group>
    <arm_group_label>SYM-1219 Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SYM-1219 High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Administered orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SYM-1219</intervention_name>
    <arm_group_label>SYM-1219 Low Dose</arm_group_label>
    <arm_group_label>SYM-1219 High Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Are females at least 18 years of age in good general health who are not menopausal.

          -  Have a clinical diagnosis of bacterial vaginosis, defined as having all of the
             following criteria:

               -  Off-white (milky or gray), thin, homogeneous vaginal discharge

               -  Vaginal pH ≥ 4.7

               -  Presence of clue cells of  ≥ 20% of the total epithelial cells on microscopic
                  examination of the vaginal saline wet mount

               -  A positive 10% KOH Whiff test.

          -  Have a Gram stain slide Nugent score ≥ 4 at the Baseline visit (Day 1)

        Exclusion Criteria:

          -  Are pregnant, lactating, or planning to become pregnant during the study.

          -  Are suspected clinically (or confirmed diagnostically) of having alternative causes
             of vaginal symptoms including candidiasis, Chlamydia trachomatis, Trichomonas
             vaginalis, Neisseria gonorrhoeae or Herpes simplex.

          -  Have received antifungal or antimicrobial therapy (systemic or intravaginal) within
             14 days prior to the Baseline visit (Day 1).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nikki Adetoro</last_name>
    <phone>609-722-7250</phone>
    <phone_ext>112</phone_ext>
    <email>Nadetoro@symbiomix.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>North Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Roswell</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Saginaw</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Lawrenceville</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Plainsboro</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>New Bern</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 28, 2014</lastchanged_date>
  <firstreceived_date>May 16, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vaginosis, Bacterial</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
